NMT Medical, Inc. Adds Intellectual Property to Its Sealed Bid Sale of Friday, June 10, 2011 at Twelve O'Clock Noon

By Joseph F. Finn Jr. C.p.a., PRNE
Monday, May 16, 2011

WELLESLEY HILLS, Massachusetts, May 17, 2011 - NMT Medical, Inc. adds intellectual property, which has been assigned to
Joseph F. Finn, Jr., C.P.A. ("Finn") of the firm Finn, Warnke & Gayton, LLP
to be liquidated for the benefit of NMT Medical creditors, to its sealed bid
sale of June 10, 2011.

The intellectual property is:

    -- Nitinol and Other Novel Implants for Septal Defect Repair
    -- Radiofrequency Technology for Closure of Patent Foramen Ovale (PFO)
    -- Adhesive Technology for Bonding of Patent Foramen Ovale (PFO)
    -- Suturing and Clip Technology for Closure of Patent Foramen Ovale (PFO)
    -- Devices for Left Atrial Appendage (LAA) Obliteration and Remodeling
    -- Transseptal Puncture Technology
    -- Catheter-Related Technologies
    -- Shape-Memory Related Technology
    -- Distal Protection/Embolic Protection System
    -- Anastomosis Devices

The intellectual property, patents, etc. will be sold at a sealed bid
sale on Friday, June 10, 2011 at noon. Persons interested in bidding must
sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's
Office - jffinnjr@finnwarnkegayton.com or +1-781-237-8840. They will then
receive a bid package.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is a founding partner of the firm Finn,
Warnke & Gayton (www.finnwarnkegayton.com), Certified Public
Accountants of Wellesley Hills, Massachusetts. He works primarily in the area
of management consulting for distressed enterprises, bankruptcy accounting
and related matters, such as assignee for the benefit of creditors and
liquidating agent for a corporation. He has been involved in a number of loan
workouts and bankruptcy cases for thirty-seven (37) years. His most recent
Assignments for the Benefit of Creditors in the biotech field include
Spherics, Inc., ActivBiotics, Inc., Prospect Therapeutics, Inc., EPIX
Pharmaceuticals, Inc. and Source MDx.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at
+1-781-237-8840 or jffinnjr@finnwarnkegayton.com

.

Health News

May 17 News

YOUR VIEW POINT
NAME : (REQUIRED)
MAIL : (REQUIRED)
will not be displayed
WEBSITE : (OPTIONAL)
YOUR
COMMENT :